Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Accumulation of intracellular neurofibrillary tangles (NFTs) consisting of microtubule-associated protein tau is a major
hallmark of Alzheimer锟絪 disease (AD) and related neurodegenerative diseases regarded as 锟絫auopathies锟�. Findings of tau gene
mutations in FTDP-17-tau families have provided direct evidence that tau abnormalities alone can induce neurodegenerative
disorders. Therefore, visualization of tau accumulation would offer a reliable, objective indicator to diagnose of tauopathy
and to assess the disease progression. Positron emission tomography (PET) imaging of tau lesions is currently available using
several tau PET ligands including [11C]PBB3. However, more compelling in vivo and neuropathological evidence supporting
binding of PBB3 to tau lesions in diverse tauopathies (e.g., AD, Progressive supranuclear palsy, Corticobasal degeneration,
Argyrophilic grain disease, Pick锟絪 disease) is still required since the presence of tau pathologies in scanned subjects has not
been confirmed in the aforementioned clinical PET assay. PBB3 is a fluorescent compound, and is accordingly supposed to
be useful for multimodal imaging studies, potentially allowing us to validate its binding to diverse tau inclusions (e.g., NFTs,
globus NFTs, astrocytic plaques, tufted astrocytes, coiled bodies, Pick bodies, and ballooned neurons) by histological methods.
The author will present progress of pathological characteristics of PBB3 binding on tau lesions in brains of human subjects
with various tauopathies and tau transgenic mice. Moreover, ongoing studies will be introduced for the usefulness of tau PET
ligands in the early detection of tauopathies.
Biography
Naruhiko Sahara received his BS from the Tokyo University of Science, Canada in 1988. MS from Tokyo University of Science in 1990 in the Department of
Biochemistry and PhD from Tokyo University of Science in the Department of Biochemistry in 1998. From 1992-1998, he worked as a Research Technologist in
the Department of Molecular Biology in Tokyo Institute of Psychiatry, Tokyo, Japan. 1998-2000 as a Research associate in Department of Neuroscience, Osaka
City University, Japan. 2000-2003 Research fellow in Laboratory of Neurochemistry, Mayo Clinic, Jacksonville. From 2003-2006, he worked as a Staff Scientist
in Laboratory for Alzheimer锟絪 Disease, Brain Science Institute, The Institute of Physical and Chemical Research (RIKEN) in Japan. 2006-2008 he was Deputy
Laboratory Head in Laboratory for Alzheimer锟絪 Disease, Brain Scinence Institute, RIKEN in Japan. From 2008-2009, Senior Research Associate, Laboratory of
Neurodegenerative Disease Modeling, Mayo Clinic. 2009-2010, he worked as an Associate Consultant in Laboratory of Neurodegenerative Disease Modeling in
Mayo Clinic, Jacksonville. 2010-2013 as Assistant Professor in Department of Neuroscience, Center for Translational Research in Neurodegenerative Disease,
College of Medicine, University of Florida, Gainesville. 2013-present he is working as a Senior Researcher and Assistant Director, Neuromolecular Dynamics Team
in Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan.
Relevant Topics
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, 黑料网 Journals
